Clik here to view.
Aurion Biotech Announces IOTA Cell Therapy Trial
SEATTLE & BOSTON & TOKYO Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, today announced...
View ArticleClik here to view.
Synaffix宣布与普方生物达成价值2.46亿美元的ADC合作
荷兰阿姆斯特丹 (美国商业资讯)– Synaffix B.V.,一家专注于将其临床阶段抗体偶联药物（ADC）技术平台商业化的生物技术公司，今天宣布与普方生物，一家抗肿瘤生物药研发公司，签署了一份非排他性的许可协议，该技术可以使ADC药物具有同类最佳的治疗指数。 基于此次合作，Synaffix将提供多个新型的有效载荷连接子技术，包括GlycoConnect™糖苷偶联技术和极性的...
View ArticleClik here to view.
Santen and IAPB Taking Action to Implement the First Ever UN General Assembly...
OSAKA, Japan Santen Pharmaceutical Co., Ltd. (“Santen”) announced today that Santen, in partnership with the International Agency for the Prevention of Blindness (IAPB), will take action to...
View ArticleClik here to view.
Wyss中心与Artiria Medical合作加速脑血管痉挛的新型疗法
日内瓦 (美国商业资讯)–Wyss中心(Wyss Center)和Artiria Medical今天宣布建立新的合作伙伴关系，以加速一项新技术的转化。该技术有望降低卒中患者的死亡率并提高其生活品质。Artiria...
View ArticleClik here to view.
Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic...
SOUTH SAN FRANCISCO, Calif. & KAWASAKI, Japan Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its...
View ArticleClik here to view.
Twist Bioscience社がMOLCURE社の人工知能技術を導入し、抗体医薬品の探索を強化
米国カリフォルニア州サウス ビジネスワイヤ） — サンフランシスコと日本川崎 – 半導体プラットフォームを用いた高品質な合成DNAを提供し、顧客の成功を支援しているTwist Bioscience社（Nasdaq:...
View ArticleClik here to view.
Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer
HOUSTON ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that Dr. Revati Shreeniwas...
View ArticleClik here to view.
ERS Genomicsと日本エスエルシーがCRISPR/Cas9ライセンス契約に署名
DUBLIN & SHIZUOKA, Japan （ビジネスワイヤ） –ERS Genomics...
View ArticleClik here to view.
iXensor Levels Up PixoTest® COVID-19 Ag Test With the Launch of PixoHealth...
TAIPEI, Taiwan iXensor Co., Ltd. (6734.TWO) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005852/en/ PixoHealth Pass Admin...
View ArticleClik here to view.
参天制药和国际防盲协会合作，以实际行动执行联合国大会首个确认眼部健康与可持续发展之间存在联系的决议
日本大阪 (美国商业资讯)–参天制药株式会社（Santen Pharmaceutical Co., Ltd.，简称“参天”）今天宣布，公司将与国际防盲协会(International Agency for the Prevention of Blindness,...
View ArticleClik here to view.
Clik here to view.
Deargen Signs Agreement With Sookmyung Women’s University Research & Business...
SEOUL, South Korea Deargen (President: Kilsoo Kang), an artificial intelligence (AI)-powered drug discovery and development company, announced on July 27 that it signed an agreement with Sookmyung...
View ArticleClik here to view.
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy...
View ArticleClik here to view.
ImmunoScape Appoints Renowned Immuno-Oncology Expert Adrian Woolfson, BM BCh,...
SINGAPORE & SAN DIEGO ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced that Adrian Woolfson,...
View ArticleClik here to view.
FDA Clears Promega OncoMate™ MSI Dx Analysis System
MADISON, Wis. Oncologists and pathologists in the United States can now access a new in vitro diagnostic (IVD) test that screens for Lynch syndrome in patients with colorectal cancer. The OncoMate™...
View ArticleClik here to view.
株式会社KORTUCはピボタル第II相試験（革新的ながん治療放射線増感剤）の加速にむけ、アクサ生命より資金調達を実施
ロンドン & ニューヨーク & 東京 （ビジネスワイヤ） — がんの放射線治療効果を高める放射線増感剤KORTUCの臨床開発及び製品開発を行なうスタートアップ企業、株式会社KORTUC（以下 KORTUC）はアクサ生命保険株式会社（以下 アクサ生命）からの資金調達を実施しました。 KORTUCは本資金調達により、英国で実施中の承認申請取得の為の試験（以下...
View ArticleClik here to view.
KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II...
LONDON & NEW YORK & TOKYO Today KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the...
View ArticleClik here to view.
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and...
CAMBRIDGE, Mass. & KAWASAKI CITY, Kanagawa Prefecture, Japan Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and PeptiDream, Inc. (Tokyo Stock Exchange:...
View ArticleClik here to view.
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on...
View ArticleClik here to view.